60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives Sell (E+) Rating from Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating reissued by stock analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, January 10th.

60 Degrees Pharmaceuticals Price Performance

SXTP stock traded up $0.00 during trading on Friday, hitting $0.83. 322,501 shares of the stock traded hands, compared to its average volume of 926,419. The stock has a market cap of $1.90 million, a price-to-earnings ratio of -0.08 and a beta of 4.40. 60 Degrees Pharmaceuticals has a 1 year low of $0.70 and a 1 year high of $11.01. The firm’s 50 day moving average is $1.19 and its two-hundred day moving average is $1.02.

Insider Buying and Selling

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow bought 35,823 shares of 60 Degrees Pharmaceuticals stock in a transaction dated Monday, December 9th. The shares were purchased at an average cost of $1.27 per share, for a total transaction of $45,495.21. Following the acquisition, the chief executive officer now directly owns 94,580 shares in the company, valued at approximately $120,116.60. This represents a 60.97 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. In the last three months, insiders have acquired 66,372 shares of company stock valued at $82,410. Corporate insiders own 10.27% of the company’s stock.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.